Setelah dicabutnya PPKM, terjadi peningkatan aktivitas sosial ekonomi masyarakat, yang dapat menyebabkan peningkatan kasus konfirmasi dan mortalitas COVID-19. Pemerintah telah melakukan vaksinasi COVID-19 untuk menurunkan mortalitas COVID-19 di Indonesia. DKI Jakarta sebagai ibu kota negara, menyumbangkan 16-17% perekonomian nasional, memiliki cakupan dosis boosternya masih rendah (53,9%). Penelitian ini menilai pengaruh status, homogenitas dan jenis vaksin booster secara kohort retrospektif menggunakan data Dinas Kesehatan DKI Jakarta 2023. Jumlah sampel 1069 partisipan dengan proporsi 17-45 tahun (44,62%), perempuan (56,03%), domisili DKI Jakarta (97,01%), tanpa komorbid (73,26%), mendapatkan booster (60,80%) booster heterolog (49,67%), luaran penelitian hidup (68,94%). Resiko kematian dipengaruhi oleh interaksi komorbiditas dengan status maupun jenis vaksin booster secara sinergisme. Proporsi kematian karena interaksi adalah 4,76%. Risiko kematian vaksin booster homolog 1,33 dibandingkan heterolog (0,83-2,13 p value 0,232). Pasien dengan komorbiditas dan tidak vaksin booster memiliki risiko kematian tertinggi ditinjau dari status vaksin booster (reference mendapat vaksin booster, RR 6,93 95% CI 5,07-9,48 dan p value = 0,000) maupun jenis vaksin booster (reference mendapat vaksin booster heterolog, RR 6,97 95% CI 4,98-9,76 dan p value = 0,000). Peneliti merekomendasikan pemberian vaksin booster, terutama heterolog booster, pada kelompok komorbid untuk mencegah kematian COVID-19.
After revocation of PPKM, socioeconomic activity increased, lead to escalation of confirmed cases and mortality COVID-19. The government conducted vaccination to reduce COVID-19 mortality in Indonesia. DKI Jakarta the nation's capital, contributing 16-17% of national economy, has only 53,9% booster dose coverage. This study assessed the influence of status, homogeneity and type of booster vaccine in retrospective cohort using DKI Jakarta Health Service 2023 data. The sample was 1069 with 17-45 years (44.62%), female (56.03%), domiciled in DKI Jakarta (97.01%), without comorbidities (73.26%), received booster (60.80%), heterologous booster (49.67%) and alive (68.94%). The mortality risk is influenced by interaction of comorbidities with status and type of booster vaccine synergistically. The proportion of deaths due to interactions was 4.76%. The mortality risk of homologous booster was 1.33 compared to heterologous (0.83-2.13 p value 0.232). Patients with comorbidities and no booster have the highest risk in terms of booster status (reference received booster, RR 6.93 95% CI 5.07-9.48 and p value = 0.000) and type (reference received vaccine heterologous booster, RR 6.97 95% CI 4.98-9.76 and p value = 0.000). Researchers recommend giving booster, especially heterologous, to comorbid groups to prevent COVID-19 deaths.
NessaNovarisa-Tesis-FKM-Full Text-2024.pdf ::